Clinical Trial Update: Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee [Phase 2]

View source ↗

Summary

A Phase 2 trial of zoledronic acid for spontaneous osteonecrosis of the knee has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteonecrosis

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis | Conditions: Osteonecrosis | Phase 2 | Status: WITHDRAWN